GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Compass Pathways announced positive results from its second Phase 3 trial of synthetic psilocybin COMP360 for treatment-resistant depression, showing a 3.8-point reduction in depression scores. The company plans to meet with the FDA to discuss a rolling approval application.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07604207 |
Multi-organ Imaging of Microvascular and Metabolic Function |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07600801 |
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B |
NOT_YET_RECRUITING | |
| NCT07597239 |
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization |
ACTIVE_NOT_RECRUITING | NA |
| NCT07589985 |
Hep Mec Cohort in Zambia |
RECRUITING | |
| NCT07588802 |
Effect of Opioid-Sparing Anesthesia on Postoperative Opioid Consumption and Pain in Elderly Patients Undergoing Spine Surgery |
NOT_YET_RECRUITING | PHASE2 |
| NCT07588581 |
Personalized Antisense Oligonucleotide for A Single Participant With UBTF Gene Mutation |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT07586397 |
HIPS Feasibility Randomized Controlled Trial |
NOT_YET_RECRUITING | NA |
| NCT07569367 |
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum |
NOT_YET_RECRUITING | |
| NCT07569250 |
Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization |
NOT_YET_RECRUITING | NA |
| NCT07568509 |
Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease |
RECRUITING | EARLY_PHASE1 |
